Vanderbilt University Medical Center | Vanderbilt - Ingram Cancer Center

Research site

(Unclaimed)

Location

3322 West End Avenue Suite 1000, Nashville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

ASTX727

Teclistamab

Daratumumab

DVd

Azacitidine

Doxorubicin

DPd

TTI-101

Vinorelbine

Parent organization

This site is a part of Vanderbilt University Medical Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 24 total trials

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho...

Invitation-only

Myelodysplastic Syndromes

Acute Myeloid Leukemia

Drug: ASTX727

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1)

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase...

Enrolling

Advanced or Metastatic Colorectal Cancer

Biological: Amivantamab IV

Biological: Oxaliplatin

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and t...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Daratumumab

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the...

Active, not recruiting

Relapsed/ Refractory Multiple Myeloma

Drug: PD-1 Inhibitor

Drug: Talquetamab

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with p...

Active, not recruiting

Multiple Myeloma

Drug: Dexamethasone

Drug: Teclistamab

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants:* Participants rec...

Enrolling

Beta-thalassemia

Myelodysplastic Syndromes (MDS)

Drug: Luspatercept

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (co...

Enrolling

NSCLC Stage IV

Drug: N-803

Drug: Prior failed checkpoint inhibitor

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carci...

Active, not recruiting

Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

Drug: Cisplatin/Carboplatin; 5FU

Drug: pembrolizumab

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Active, not recruiting

Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

Drug: evorpacept

Drug: pembrolizumab

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, un...

Enrolling

Solid Tumor

Malignant Peripheral Nerve Sheath Tumors

Drug: MRTX1719

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

The primary objective of this phase III trial is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment...

Active, not recruiting

Leiomyosarcoma

Drug: Lurbinectedin

Drug: Doxorubicin

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase...

Enrolling

Cancer

Drug: cetuximab

Drug: FOLFIRI